stockgist
HomeTop MoversCompaniesConcepts

Market

  • Top Movers
  • Companies
  • Concepts

SEC Filings

  • AI Filing Analysis
  • Financial Reports
  • Current Reports
  • IPO Filings

Ownership

  • Institutional Holdings
  • Insider Trading

About

  • Data updates every 5 min
  • SEC EDGAR Source
© 2025–2026 StockGist|Information only, not investment advice
    1. Companies
    2. FEMY
    stockgist
    HomeTop MoversCompaniesConcepts
    FEMY logo

    Femasys Inc.

    FEMY
    NASDAQ
    Healthcare
    Medical - Instruments & Supplies
    Suwanee, GA, US69 employeesfemasys.com
    $0.44
    +0.02(4.84%)

    Mkt Cap $13M

    $0.34
    $1.24

    52-Week Range

    At a Glance

    AI-generated

    A year of accelerating commercial traction offset by acute liquidity constraints—revenue surged 41% driven by FemBloc's European launch, yet the company faces a going concern warning with cash runway extending only to Q3 2026.

    Revenue breakdown: Business Segment (100%).

    8-K
    Femasys Inc. appointed John Canning as Chief Operating Officer effective March 30, 2026, with a $450,000 base salary and 150,000-share inducement stock option grant.

    $13M

    Market Cap

    $2M

    Revenue

    -$20M

    Net Income

    Employees69
    Fundamentals

    How The Business Makes Money

    Revenue by Segment

    Business Segment100%($4M)

    Revenue by Geography

    US62.9%($2M)
    Non Us37.1%($1M)
    Activity

    What Changed Recently

    Management Change
    Mar 31, 2026

    | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | |---|---|

    Delisting
    Jan 14, 2026

    Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on July 16, 2025, Femasys Inc. (the

    Financial Results
    Mar 30, 2026

    | Results of Operations and Financial Condition. | |---|---| On March 31, 2026 Femasys Inc. (the “Company”) announced its financial results for the year ended D

    Management Change+3 More
    Mar 19, 2026

    . Entry into a Material Definitive Agreement. As previously announced, pursuant to the Securities Purchase Agreement dated as of November 3, 2025, by and among

    Peer Companies

    CompanyPriceChangeMarket CapP/E
    HBIOHarvard Bioscience, Inc.$5.16+1.38%$23M-0.4
    EKSOEkso Bionics Holdings, In...$9.28-12.91%$23M-2.2
    DAREDaré Bioscience, Inc.$1.75-8.11%$17M-1.0
    APLMApollomics, Inc.$14.95+1.53%$16M-0.6
    COCHEnvoy Medical, Inc.$0.76+7.62%$16M-0.6
    VVOSVivos Therapeutics, Inc.$1.33+2.11%$8M-0.8
    BCTXBriaCell Therapeutics Cor...$4.08-1.57%$8M-0.3
    CRISCuris, Inc.$0.55+3.19%$7M-12.8
    Analyst View
    Company Profile
    CIK0001339005
    ISINUS31447E1055
    CUSIP31447E105
    Phone770 500 3910
    Address3950 Johns Creek Court, Suwanee, GA, 30024, US
    SEC EDGAR

    Market

    • Top Movers
    • Companies
    • Concepts

    SEC Filings

    • AI Filing Analysis
    • Financial Reports
    • Current Reports
    • IPO Filings

    Ownership

    • Institutional Holdings
    • Insider Trading

    About

    • Data updates every 5 min
    • SEC EDGAR Source
    © 2025–2026 StockGist|Information only, not investment advice